Stephanie Letney
Family Medicine · Cleveland, OKNPI 1114311354
Payments from drug & device makers
Across 139 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$438
- GSK$361
- Lilly USA, LLC$261
- AstraZeneca$257
- Amgen$138
- Pfizer$125
- plus $596 from 16 others
What the payments were for
- Food & beverage$2,176100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 36 | $438 |
| GSK | 23 | $361 |
| Lilly USA, LLC | 16 | $261 |
| AstraZeneca | 15 | $257 |
| Amgen | 10 | $138 |
| Pfizer | 4 | $125 |
| Novo Nordisk | 7 | $111 |
| Merck | 7 | $99 |
| Boehringer Ingelheim | 3 | $53 |
| Otsuka America Pharmaceutical, Inc. | 3 | $51 |
| Astellas Pharma US Inc | 2 | $47 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $46 |
| Novartis | 2 | $34 |
| Exact Sciences | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $21 |
| Sunovion Pharmaceuticals Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $17 |
| Biogen | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Abbott | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $13 |
How this compares
$2,176 in reported general payments places this provider in the 70th percentile of 1,730 family medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 58 | $81,036 |
| MounjaroTirzepatide | 57 | $69,989 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 61 | $62,501 |
| FarxigaDapagliflozin Propanediol | 39 | $47,251 |
| EliquisApixaban | 37 | $46,462 |
| JardianceEmpagliflozin | 21 | $24,169 |
| Nurtec OdtRimegepant Sulfate | 16 | $20,022 |
| TrulicityDulaglutide | 20 | $19,103 |
| MyrbetriqMirabegron | 12 | $13,594 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,444 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $9,612 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,911 |
| Repatha SyringeEvolocumab | 12 | $5,235 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 95 | $2,005 |
| Rosuvastatin Calcium | 139 | $1,915 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $261 | $89,09277 claims |
| Novo NordiskOzempic | $111 | $81,03658 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $361 | $72,11381 claims |
| PfizerEliquis, Nurtec Odt | $125 | $66,48453 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $257 | $57,69556 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $53 | $30,08032 claims |
| Astellas Pharma US IncMyrbetriq | $47 | $13,59412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,730 family medicine providers in Oklahoma.
Other family medicine in Cleveland
- Carl GriffinOklahoma City$28.2M
- Lisa ConneryNorman$15.6M
- Kyle RicknerYukon$14.7M
- Robert LockwoodYukon$8.6M
- Steven CoxNorman$6.9M
- Alexander FrankOklahoma City$3.1M
- Rachel AndersonNorman$2.8M
- Robert WestcottLindsay$1.6M
- Charles LunnOklahoma City$1.4M
- Jeffrey ChasteenTulsa$820K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.